Brensocatib Approval Sparks New Questions in Bronchiectasis Research: James D. Chalmers, MBChB, PhD

In the final clip, James D. Chalmers, MBChB, PhD, notes that while the FDA approval of brensocatib is a milestone, questions remain on optimal patient selection, long-term benefits, and further targeting inflammation.